natgillin/translations-raw huggingface dataset:
The frequency of possible side effects listed below is defined using the following convention: common (affects 1 to 10 users in 100); uncommon (affects 1 to 10 users in 1,000); rare (affects 1 to 10 
Pogostnost možnih spodaj navedenih neželenih učinkov je opredeljena po naslednjem dogovoru: pogosti (pojavijo se pri 1 do 10 od 100 bolnikov); občasni (pojavijo se pri 1 do 10 od 1.000 bolnikov); redki (pojavijo se pri 1 do 10 od 10.000 bolnikov).
Discontinuation of treatment due to non-procedural bleeding was more common for ticagrelor (2.9%) than for clopidogrel (1.2%; p<0.001). 
Prekinitve zdravljenja zaradi krvavitev, nepovezanih s postopki, so bile s tikagrelorjem pogostejše (2,9 %) kot s klopidogrelom (1,2 %, p < 0,001).
In female rats, ticagrelor at high dose showed an increased incidence of uterine tumors (adenocarcinomas) and an increased incidence of hepatic adenomas. 
Pri podganjih samicah je tikagrelor v velikih odmerkih spremljala večja incidenca tumorjev maternice (adenokarcinomov) in večja incidenca adenomov jeter.
The expected effect of excessive Possia dosing is prolonged duration of bleeding risk associated with platelet inhibition. 
Pričakovani učinek čezmernega odmerjanja zdravila Possia je podaljšanje tveganja krvavitev, povezano z zavrtjem trombocitov.
Effects of other medicinal products on Possia 
Učinki drugih zdravil na zdravilo Possia
If you get any side effects, talk to your doctor or pharmacist, but do not stop taking Possia until you have spoken to them. 
Če opazite kateri koli neželeni učinek, se posvetujte s svojim zdravnikom ali s farmacevtom, vendar ne nehajte jemati zdravila Possia, dokler niste govorili z njim.
Dyspnoea was reported by 13.8% of patients treated with Possia and by 7.8% of patients treated with clopidogrel. 
Dispneja je bila opisana pri 13,8 % bolnikov, zdravljenih z zdravilom Possia, in pri 7,8 % bolnikov, zdravljenih s klopidogrelom.
This is because Possia can affect the way some medicines work and some medicines 
Zdravilo Possia namreč lahko vpliva na delovanje nekaterih zdravil in nekatera zdravila lahko vplivajo na zdravilo Possia.
Its use in patients with moderate to severe hepatic impairment is therefore contraindicated (see section 4.3, 4.4 and 5.2). 
Njegova uporaba pri bolnikih z zmerno do hudo okvaro jeter je zato kontraindicirana (glejte poglavja 4.3, 4.4 in 5.2).
Women should use appropriate contraceptive measures to avoid pregnancy while taking this medicine. 
Ženske morajo med jemanjem tega zdravila uporabljati ustrezno kontracepcijsko zaščito za preprečitev nosečnosti.
Ingestion of a high-fat meal resulted in a 21% increase in ticagrelor AUC and 22% decrease in the active metabolite Cmax but had no effect on ticagrelor Cmax or the AUC of the active metabolite. 
Zaužitje zelo mastnega obroka je povzročilo 21 % povečanje tikagrelorjeve AUC in 22 % zmanjšanje Cmax aktivnega presnovka, ni pa vplivalo na Cmax tikagrelorja ali AUC aktivnega presnovka.
• You have moderate to severe liver disease 
• če imate zmerno do hudo bolezen jeter.
• History of intracranial haemorrhage (see section 4.8). 
• Anamneza intrakranialne krvavitve (glejte poglavje 4.8).
Patients can be switched from clopidogrel to ticagrelor without any interruption of antiplatelet effect (see section 4.2). 
Bolniki lahko preidejo s klopidogrela na tikagrelor brez prekinitve antiagregacijskega učinka (glejte poglavje 4.2).
P-glycoprotein (P-gp) substrates (including digoxin, cyclosporin) Concomitant administration of Possia increased the digoxin Cmax by 75% and AUC by 28%. 
Substrati P-glikoproteina (P-gp) (vključno z digoksinom, ciklosporinom) Sočasna uporaba zdravila Possia je povečala Cmax digoksina za 75 % in njegovo AUC za 28 %.
Patients self-identified as Black had an 18% lower bioavailability of ticagrelor compared to Caucasian patients. 
Bolniki, ki so se opredelili za črnce, so imeli 18 % manjšo biološko uporabnost tikagrelorja kot bolniki-belci.
Marketing Authorisation Holder and Manufacturer 
Imetnik dovoljenja za promet in izdelovalec
Patients in PLATO receiving ticagrelor took a variety of statins, with no concern of an association with statin safety among the 93% of the PLATO cohort taking these medicinal products. 
Bolniki, ki so v študiji PLATO dobivali tikagrelor, so jemali različne statine; pri 93 % kohorte PLATO, ki je jemala ta zdravila, ni bilo nobenih pomislekov v zvezi z varnostjo statinov.
Patients of Asian descent have a 39% higher mean bioavailability compared to Caucasian patients. 
Bolniki azijskega porekla imajo 39 % večjo povprečno biološko uporabnost kot bolniki-belci.
Possia contains the active substance called ticagrelor. 
Zdravilo Possia vsebuje zdravilno učinkovino, imenovano tikagrelor.
No studies on the effects of Possia on the ability to drive and use machines have been performed. 
Študije o vplivu zdravila Possia na sposobnost vožnje in upravljanja s stroji niso bile izvedene.
Co-administration of ticagrelor with doses of simvastatin exceeding 40 mg daily could cause adverse effects of simvastatin and should be weighed against potential benefits. 
Sočasna uporaba tikagrelorja in več kot 40 mg simvastatina na dan lahko povzroči neželene učinke simvastatina in jo je treba pretehtati glede na možne koristi.
The metabolite parent ratios are 0.28 for Cmax and 0.42 
Razmerje presnovek matična snov je za Cmax 0,28 in za AUC 0,42.
Studies in rats and rabbits have shown reproductive toxicity, with slightly reduced maternal body weight gain and reduced neonatal viability and birth weight, with delayed growth. 
Študije na podganah in kuncih so pokazale reproduktivne toksične učinke z rahlo zmanjšanim porastom telesne mase samic, manjšo viabilnostjo novoskotenih mladičev, manjšo telesno maso ob skotitvi ter upočasnjeno rast.
(%/yr) 
ARRa (%/leto)
This belongs to a group of medicines called 
To zdravilo spada v skupino zdravil, imenovanih antiagregacijska zdravila.
• Moderate to severe hepatic impairment (see section 4.2, 4.4 and 5.2). 
• Zmerna do huda okvara jeter (glejte poglavja 4.2, 4.4 in 5.2).
A combined efficacy and safety composite (CV death, MI, stroke, or PLATO-defined ‘Total Major' bleeding) indicates that the benefit in efficacy of Possia compared to clopidogrel is not offset by the major bleeding events (ARR 1.4%, RRR 8%, HR 0.92; p=0.0257) over 12 months after ACS. 
Kombinirana sestavljena točka učinkovitosti in varnosti (KV smrt, MI, možganska kap ali "vse hude" krvavitve po opredelitvi PLATO) kaže, da koristi glede učinkovitosti zdravila Possia v primerjavi s klopidogrelom ne odpravijo hudi krvavitveni dogodki (ARR 1,4 %, RRR 8 %, razmerje ogroženosti 0,92, p = 0,0257) v 12 mesecih po akutnem koronarnem sindromu.
In the phase 3 pivotal trial (PLATO [PLATelet Inhibition and Patient Outcomes], 18,624 patients) key exclusion criteria included an increased risk for bleeding, clinically important thrombocytopenia or anaemia, previous intracranial bleed, gastrointestinal bleed within the past 6 months or major surgery within the past 30 days. 
V ključnem preskušanju 3. faze PLATO ([PLATelet Inhibition and Patient Outcomes], 18.624 bolnikov) so bili med ključnimi merili za nevključitev večje tveganje krvavitev, klinična pomembna trombocitopenija ali anemija, predhodna intrakranialna krvavitev, gastrointestinalna krvavitev v zadnjih 6 mesecih ali večja operacija v zadnjih 30 dneh.
Effects of Possia on other medicinal products 
Učinki zdravila Possia na druga zdravila
• The active substance is ticagrelor. 
• Zdravilna učinkovina je tikagrelor.
CYP2C19 and ABCB1 genotyping of 10,285 patients in PLATO provided associations of genotype groups with PLATO outcomes. 
Na podlagi genotipizacije 10285 bolnikov glede CYP2C19 in ABCB1 v študiji PLATO so analizirali povezanost genotipskih skupin z izidi v študiji PLATO.
Ticagrelor has not been evaluated in a paediatric population (see section 4.2 and 5.1). 
Pediatrična populacija Tikagrelor v pediatrični populaciji ni ovrednoten (glejte poglavji 4.2 in 5.1).
To study the occurrence of ventricular pauses and other arrhythmic episodes during PLATO, investigators performed Holter monitoring in a subset of nearly 3000 patients, of whom approximately 2000 had recordings both in the acute phase of their ACS and after one month. 
Za proučitev pojavljanja ventrikularnih pavz in drugih epizod motenj srčnega ritma so v študiji PLATO opravili holtersko monitorizacijo v podskupini skoraj 3000 bolnikov, od katerih jih je približno 2000 imelo posnetke tako v akutni fazi akutnega koronarnega sindroma kot po enem mesecu.
Intracranial bleeding: There were more intracranial non-procedural bleeds with ticagrelor (n=27 bleeds in 26 patients, 0.3%) than with clopidogrel (n=14 bleeds, 0.2%), of which 11 bleeds with ticagrelor and 1 with clopidogrel were fatal. 
Intrakranialna krvavitev: S tikagrelorjem je bilo več intrakranialnih krvavitev, nepovezanih s postopki (n = 27 krvavitev pri 26 bolnikih, 0,3 %) kot s klopidogrelom (n = 14 krvavitev, 0,2 %); od teh je bilo smrtnih 11 krvavitev s tikagrelorjem in 1 s klopidogrelom.
If you take more Possia than you should, talk to a doctor or go to hospital straight away. 
Če ste vzeli večji odmerek zdravila Possia, kot bi smeli Če vzamete več zdravila Possia, kot bi smeli, se morate takoj posvetovati z zdravnikom ali iti v bolnišnico.
The use of Possia is contraindicated in patients with active pathological bleeding, in those with a history of intracranial haemorrhage, and in patients with moderate to severe hepatic impairment (see section 4.3). 
Uporaba zdravila Possia je kontraindicirana pri bolnikih z aktivno patološko krvavitvijo, bolnikih z anamnezo intrakranialne krvavitve in bolnikih z zmerno do hudo okvaro jeter (glejte poglavje 4.3).
Tabulated summary of adverse reactions The following adverse reactions have been identified following studies with Possia (Table 1). 
Tabeliran povzetek neželenih učinkov Po študijah z zdravilom Possia so ugotovili naslednje neželene učinke (preglednica 1).
In rats minor developmental anomalies were seen at a maternal toxic dose (safety margin of 5.1). 
Pri podganah so pri odmerkih, toksičnih za samice, opazili manjše razvojne nepravilnosti (varnostna meja 5,1).
90% of patients had final extent IPA 
90 % bolnikov je imelo končno IPA do 2. ure po odmerku > 70 %.
In clinical pharmacology studies, the exposure (Cmax and AUC) to ticagrelor in Japanese subjects was approximately 40% (20% after adjusting for body weight) higher compared to that in Caucasians. 
V kliničnih farmakoloških študijah je bila izpostavljenost (Cmax in AUC) tikagrelorju pri japonskih preiskovancih približno 40 % večja (20 % večja po korekciji za telesno maso) kot pri belcih.
In the event of overdose, observe for these potential adverse reactions and consider ECG monitoring 
V primeru prevelikega odmerjanja je treba bolnika spremljati glede teh možnih neželenih učinkov in v poštev pride EKG-nadzor.
For any information about this medicine, please contact the local representative of the Marketing 
Za vse morebitne nadaljnje informacije o tem zdravilu se lahko obrnete na predstavništvo imetnika dovoljenja za promet z zdravilom:
However, platelets can also form clots inside diseased blood vessels in the heart and brain. 
Vendar lahko trombociti tudi povzročijo nastanek krvnih strdkov v bolnih žilah v srcu ali možganih.
Based on a relationship observed in PLATO between maintenance ASA dose and relative efficacy of ticagrelor compared to clopidogrel, co-administration of Possia and high maintenance dose ASA (>300 mg) is not recommended (see section 5.1). 
Glede na razmerje med vzdrževalnim odmerkom ASA in relativno učinkovitostjo tikagrelorja v primerjavi s klopidogrelom, ugotovljeno v študiji PLATO, sočasna uporaba zdravila Possia in visokega vzdrževalnega odmerka ASA (> 300 mg) ni priporočljiva (glejte poglavje 5.1).
Ticagrelor should be used with caution in patients with history of asthma and/or COPD. 
Tikagrelor je treba previdno uporabljati pri bolnikih z astmo in/ali KOPB.
In addition, caution should be exercised when administering Possia concomitantly with medicinal products known to induce bradycardia. 
Poleg tega je potrebna previdnost, če je zdravilo Possia uporabljeno skupaj z zdravili, ki povzročajo bradikardijo.
CALENDAR BLISTER (14 TABLETS) 
KOLEDARSKI PRETISNI OMOT (14 TABLET)
If you have any further questions on the use of this medicine, ask your doctor or pharmacist. 
Če imate dodatna vprašanja o uporabi zdravila, se posvetujte s svojim zdravnikom ali s farmacevtom.
• Simvastatin - Co-administration of ticagrelor with simvastatin increased simvastatin Cmax by 81% and AUC by 56% and increased simvastatin acid Cmax by 64% and AUC by 52% with some individual increases equal to 2 to 3 fold. 
• Simvastatin - Sočasna uporaba tikagrelorja in simvastatina je povečala Cmax simvastatina za 81 % in njegovo AUC za 56 %; Cmax simvastatinske kisline je povečala za 64 % in njeno AUC za 52 %, pri nekaterih posameznikih pa so bila povečanja 2- do 3-kratna.
In patients with Acute Coronary Syndromes (ACS), premature discontinuation with any antiplatelet therapy, including Possia, could result in an increased risk of cardiovascular death, or myocardial infarction due to the patient's underlying disease. 
Bolnikom z akutnimi koronarnimi sindromi (ACS - Acute Coronary Syndrome) lahko prezgodnje prenehanje uporabe kateregakoli antiagregacijskega zdravila, tudi zdravila Possia, poveča tveganje kardiovaskularne smrti ali miokardnega infarkta zaradi njihove osnovne bolezni.
Pharmacokinetic studies performed with radio-labeled ticagrelor have shown that the parent compound and its metabolites are excreted in the milk of rats (see section 4.6). 
Farmakokinetične študije z radioaktivno označenim tikagrelorjem so pokazale, da se matična spojina in njeni presnovki izločajo v mleku podgan (glejte poglavje 4.6).
OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING 
C. DRUGI POGOJI IN ZAHTEVE DOVOLJENJA ZA PROMET Z ZDRAVILOM
If you stop taking Possia 
Če ste prenehali jemati zdravilo Possia
EU/1/10/656/002 180 film-coated tablets 
EU/1/10/656/001-006
There were no adverse clinical consequences associated with this imbalance (including syncope or pacemaker insertion) in this patient population (see section 5.1). 
S to razliko v tej populaciji bolnikov niso bile povezane kakšne neželene klinične posledice (vključno s sinkopo ali vstavitvijo srčnega spodbujevalnika) (glejte poglavje 5.1).
Uric acid increase 
Zvišanje sečne kisline
Therefore, due to the limited clinical experience, Possia should be used with caution in these patients (see section 5.1). 
Zato je treba zdravilo Possia zaradi skromnih kliničnih izkušenj pri takšnih bolnikih uporabljati previdno (glejte poglavje 5.1).
PLATO included patients with baseline congestive heart failure, chronic obstructive pulmonary disease, or asthma; these patients, and the elderly, were more likely to report dyspnoea. 
Študija PLATO je zajela bolnike, ki so izhodiščno imeli srčno popuščanje, kronično obstruktivno pljučno bolezen ali astmo; pri teh in pa pri starejših bolnikih je bila verjetnost dispneje večja.
Ticagrelor had no effect on male or female fertility in animals (see section 5.3). 
Plodnost Tikagrelor pri živalih ni vplival na moško ali žensko plodnost (glejte poglavje 5.3).
Since co-administration of Possia with desmopressin did not decrease template-bleeding time, desmopressin is unlikely to be effective in managing clinical bleeding events (see section 4.5). 
Sočasna uporaba zdravila Possia z dezmopresinom ni skrajšala standardiziranega časa krvavitve ("template bleeding time"), zato ni verjetno, da bi bil dezmopresin učinkovit za obvladovanje kliničnih krvavitev (glejte poglavje 4.5).
Patients with acute coronary syndromes treated with Possia and ASA showed an increased risk of non-CABG major bleeding and also more generally in bleeds requiring medical attention i.e. Major + Minor PLATO bleeds, but not Fatal or Life-threatening bleeds (see section 4.8). 
Pri bolnikih z akutnimi koronarnimi sindromi, zdravljenih z zdravilom Possia in ASA, so ugotovili večje tveganje hujših krvavitev, nepovezanih s CABG, in tudi na splošno krvavitev, ki so zahtevale zdravniško oskrbo, tj. hujših in blažjih krvavitev po PLATO, ne pa tudi življensko nevarnih krvavitev ali krvavitev s smrtnim izidom (glejte poglavje 4.8).
The higher incidence of dyspnoea with Possia is not associated with new or worsening heart or lung disease (see section 4.4). 
Possia ni povezana z novim nastankom ali poslabšanjem bolezni srca ali pljuč (glejte poglavje 4.4).
The formation of the major circulating metabolite AR-C124910XX (also active) from ticagrelor is rapid with a median tmax of approximately 2.5 hours. 
Glavni presnovek v obtoku, AR-C124910XX, (ki je tudi aktiven) nastane iz tikagrelorja hitro; mediani tmax je približno 2,5 ure.
Following an initial dose of ASA, Possia should be used with a maintenance dose of ASA of 75-150 mg (see 
Po uvodnem odmerku ASA je treba zdravilo Possia uporabljati z vzdrževalnim odmerkom ASA od 75 do 150 mg (glejte poglavje 5.1).
The major metabolite of ticagrelor is AR-C124910XX, which is also active as assessed by in vitro binding to the platelet P2Y12 ADP-receptor. 
Glavni presnovek tikagrelorja je AR-C124910XX, ki je tudi aktiven, kot je bilo ugotovljeno z vezavo na trombocitni ADP-receptor P2Y12 in vitro.
Co-administration of Possia with heparin, enoxaparin or desmopressin had no effect on activated partial thromboplastin time (aPTT), activated coagulation time (ACT) or factor Xa assays. 
Sočasna uporaba zdravila Possia s heparinom, enoksaparinom ali dezmopresinom ni vplivala na aktivirani parcialni tromboplastinski čas (aPTT), aktivirani koagulacijski čas (ACT) ali teste faktorja Xa.
Possia treatment should be initiated with a single 180 mg loading dose (two tablets of 90 mg) and then 
Zdravljenje z zdravilom Possia je treba začeti z enim 180-mg polnilnim odmerkom (dve tableti po 90 mg) in ga nadaljevati z 90 mg dvakrat na dan.
Do not use this medicine after the expiry date, which is stated on the blister and carton after EXP. 
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na pretisnem omotu in škatli poleg oznake EXP. Datum izteka roka uporabnosti se nanaša na zadnji dan navedenega meseca.
In rabbits a slight delay in hepatic maturity and skeletal development was seen in foetuses from dams at high dose without showing maternal toxicity (safety margin of 4.5). 
Pri kuncih so opazili rahel zaostanek jetrne zrelosti in razvoja okostja pri plodovih samic, ki so dobivale velike odmerke brez toksičnih učinkov na samice (varnostna meja 4,5).
Clinical pharmacology interaction studies showed that co-administration of ticagrelor with heparin, enoxaparin and ASA or desmopressin did not have any effect on the pharmacokinetics of ticagrelor or the active metabolite or on ADP-induced platelet aggregation compared with ticagrelor alone. 
Klinične farmakološke študije medsebojnega delovanja so pokazale, da sočasna uporaba tikagrelorja s heparinom, enoksaparinom in ASA ali dezmopresinom ni vplivala na farmakokinetiko tikagrelorja ali aktivnega presnovka; prav tako v primerjavi s tikagrelorjem ni vplivala na agregacijo trombocitov, izzvano z ADP.
Major Fatal/Life-threatening Bleed: Clinically apparent with >50 g/l decrease in haemoglobin or ≥4 red cell units transfused; or fatal; or intracranial; or intrapericardial with cardiac tamponade; or with hypovolaemic shock or severe hypotension requiring pressors or surgery. 
Huda krvavitev s smrtnim izidom/smrtno nevarna krvavitev: Klinično opazna z znižanjem hemoglobina > 50 g/l ali transfuzijo ≥ 4 enot eritrocitov, ali s smrtnim izidom, ali intrakranialna, ali intraperikardialna s tamponado srca, ali s hipovolemičnim šokom ali hudo hipotenzijo, ki zahteva uporabo presorjev ali operacijo.
• You are bleeding now or have bled recently inside your body, such as bleeding in your stomach or gut from an ulcer. 
• če imate ali ste nedavno imeli notranjo krvavitev, npr. krvavitev v želodec ali črevo iz razjede.
• You are due to have surgery (including dental work) at any time while taking Possia. 
• če imate predvideno operacijo (to velja tudi za zobozdravstvene posege) kadarkoli med jemanjem zdravila Possia.
Other possible side effects 
Drugi možni neželeni učinki
For oral use. 
Način uporabe Za peroralno uporabo.
Ticagrelor should be used with caution in patients with history of asthma and/or COPD (see section 4.4). 
Tikagrelor je treba previdno uporabljati pri bolnikih z astmo in/ali KOPB (glejte poglavje 4.4).
Possia can be administered with or without food. 
Zdravilo Possia se lahko jemlje s hrano ali brez nje.
Non-CABG PLATO Major bleeding was increased with ticagrelor compared clopidogrel in patients with one or more CYP2C19 loss of function alleles, but similar to clopidogrel in patients with no loss of function allele. 
Hudih, s CABG nepovezanih krvavitev po PLATO je bilo s tikagrelorjem več kot s klopidogrelom pri bolnikih, ki so imeli izgubo enega ali več funkcijskih alelov CYP2C19, a je bilo podobno kot s klopidogrelom pri bolnikih brez izgube funkcijskega alela.
Uric acid elevations: In PLATO, serum uric acid concentration increased to more than upper limit of normal in 22% of patients receiving ticagrelor compared to 13% of patients receiving clopidogrel. 
Zvišanje sečne kisline: V študiji PLATO se je koncentracija sečne kisline v serumu povečala nad zgornjo normalno mejo pri 22 % bolnikov, ki so dobivali tikagrelor, in pri 13 % tistih, ki so dobivali klopidogrel.
Ticagrelor does not interact with the ADP binding site itself, but interacts with platelet P2Y12 ADP-receptor to prevent signal 
Tikagrelor ne interagira z vezavnim mestom za ADP samim, temveč z interakcijo z ADP receptorjem P2Y12 prepreči prevajanje signalov.
Preclinical data for ticagrelor and its major metabolite have not demonstrated unacceptable risk for adverse effects for humans based on conventional studies of safety pharmacology, single and repeated dose toxicity and genotoxic potential. 
Predklinični podatki za tikagrelor in njegov glavni presnovek na podlagi običajnih študij varnostne farmakologije, toksičnosti enkratnih in ponavljajočih se odmerkov in genotoksičnega potenciala niso pokazali nesprejemljivega tveganja neželenih učinkov za človeka.
Compared with clopidogrel, patients with asthma/COPD treated with ticagrelor may have an increased risk of experiencing non-serious dyspnoea (3.29% ticagrelor versus 0.53% clopidogrel) and serious dyspnoea (0.38% ticagrelor versus 0.00% clopidogrel). 
V primerjavi s klopidogrelom imajo lahko bolniki z astmo/KOPB, ki dobivajo tikagrelor, večje tveganje ne-resne dispneje (3,29 % s tikagrelorjem v primerjavi z 0,53 % s klopidogrelom) in resne dispneje (0,38 % s tikagrelorjem v primerjavi z 0,00 % s klopidogrelom).
• Atorvastatin - Co-administration of atorvastatin and ticagrelor increased atorvastatin acid Cmax by 23% and AUC by 36%. 
• Atorvastatin - Sočasna uporaba atorvastatina in tikagrelorja je povečala Cmax atorvastatinske kisline za 23 % in njeno AUC za 36 %.
Creatinine elevations by >50% were more pronounced in patients > 75 years (ticagrelor 13.6% versus clopidogrel 8.8%), in patients with severe renal impairment at baseline (ticagrelor 17.8% versus clopidogrel 12.5%) and in patients receiving concomitant treatment with ARBs (ticagrelor 11.2% versus clopidogrel 7.1%). 
Zvišanje kreatinina za > 50 % je bilo izrazitejše pri bolnikih, starejših od 75 let (tikagrelor 13,6 % v primerjavi s klopidogrelom 8,8 %), pri bolnikih z izhodiščno hudo okvaro ledvic (tikagrelor 17,8 % v primerjavi s klopidogrelom 12,5 %) in pri bolnikih, ki so sočasno dobivali antagoniste receptorjev angiotenzina (tikagrelor 11,2 % v primerjavi s klopidogrelom 7,1 %).